India’s Elder Pharma expands its Solo range of OTC products
In order to boost its presence in the country’s rural markets, Elder Pharmaceuticals will make the new products available in smaller sizes as well. Elder Pharmaceuticals managing director
Health innovation platform developer Aditxt and its fully owned subsidiary Ignite Proteomics have announced their plans for a business combination with a strategic partner that values the latter at an implied equity value of nearly $150m.
This multi-year collaboration will come into effect, following the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. Merck Research Laboratories president Roger M. Perlmutter said: